Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1Phase 2 1

Status

Completed 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1NETWORK 1

Study Type

Interventional 4Observational 2

Sponsor

Cancer Type

Dermatologic 4Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Prostatic Neoplasms 9Leukemia, Myeloid, Acute 9Endometrial Neoplasms 8Breast Neoplasms 7Oropharyngeal Neoplasms 5Neoplasm Metastasis 5Lung Neoplasms 5Colonic Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Neoplasms 4Multiple Myeloma 4Melanoma 4Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia, Erythroblastic, Acute 4Congenital Abnormalities 4Colorectal Neoplasms 4Stomach Neoplasms 3Rectal Neoplasms 3Neuroblastoma 3Mouth Neoplasms 3Lymphoma, Follicular 3Leukemia 3Esophageal Neoplasms 3Brain Neoplasms 3

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236aldesleukin 134Cyclophosphamide 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 67dabrafenib 65fludarabine phosphate 61sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35cobimetinib 32Magnetic Resonance Spectroscopy 32Introns 30Specimen Handling 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Melanoma × Observation × Clear all
NCT00003641 2026-02-25

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
1,150 enrolled 6 charts
Dermatologic

Melanoma

NCT00975520 2024-11-27

RTN2

Melanoma and Skin Cancer Trials Limited

Phase NA Completed
50 enrolled
Dermatologic

Melanoma, Recurrence

NCT03220009 2018-10-03

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

National Cancer Institute (NCI)

Phase 2 Withdrawn
DermatologicGastrointestinalGynecologic

Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Vaginal Neoplasms, Vulvar Neoplasms

NCT00004196 2014-01-20

Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis

University of Alabama at Birmingham

Phase 3 Completed
3,000 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡